Media Center

News

AbilityPharma Announces FDA Approval of IND for Phase 2 Trial of ABTL0812 in Patients with Endometrial Cancer or Squamous Non-Small Cell Lung Cancer

December 13, 2017

Ability Pharmaceuticals announces the approval from the French Medicines Agency ANSM to initiate a Phase 1/2a Clinical Trial with ABTL0812 to treat patients with endometrial cancer or squamous lung cancer as first-line therapy in France

October 5, 2017

Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer

September 18, 2017

Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology

March 3, 2017

Ability Pharmaceuticals launches a new updated website with a fresh design

February 20, 2017

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer

December 14, 2016

Ability Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First Line Therapy in Patients with Endometrial or Squamous Lung Cancer Patients

November 22, 2016

· ABTL0812 is administered in combination with carboplatin and paclitaxel
· Vall d’Hebron Institute of Oncology (VHIO, Barcelona) and Catalan Institute of Oncology (ICO, L’Hospitalet, Barcelona) lead the study, which includes other centers in Spain and France

Ability Pharmaceuticals Enters into a Licensing Agreement with SciClone Pharmaceuticals for the Novel Anticancer Agent ABTL0812 for the China Market.

May 11, 2016

Collaboration Boosts Development of a Fully Differentiated Inhibitor of the PI3K/Akt/mTOR pathway.
ABTL0812 is currently in Phase 2 Clinical Trials to Treat Lung and Endometrial Cancers.

Ability Pharmaceuticals Receives Positive Opinion from EMA for Orphan Drug Status of ABTL0812 in Pediatric Cancer Neuroblastoma.

April 7, 2015

Ability Pharmaceuticals to Present at the 7th Annual European Life Sciences CEO Forum in Zurich, March 4-5, 2014.

February 14, 2014

ABILITY PHARMACEUTICALS Initiates Clinical Trial with its Dual mTORC1/C2 Inhibitor ABTL0812 in Patients with Lung and Pancreatic Cancer

February 5, 2014

The Spanish Medicines Agency has approved the Initiation of the Phase I/Ib Clinical Trial at Hospital Clinic Barcelona.

Ability Pharmaceuticals to Present at the 6th Annual European Life Sciences CEO Forum in Zurich, March 5-6, 2013.

February 20, 2013

ABILITY PHARMACEUTICALS awarded a 1.2 million euros grant to develop its Lipid Analog ABTL0812 for Lung and Pancreatic Cancer

February 5, 2013

The grant will fund the first-in-man phase Ib clinical trial in advanced cancer patients with refractory solid tumor
The program will be presented at the 2013 ASCO Meeting and involves the Autonomous University of Barcelona and the research institute IDIBAPS

Ability Pharmaceuticals to Present at the Biotech Showcase Event (a Satellite to JP Morgan Healthcare Conference) in San Francisco, January 7-9, 2013.

December 23, 2012

AB-Therapeutics closes 1 million euro financing round and changes the company name to Ability Pharmaceuticals

September 21, 2012

The Catalan Biopharmaceutical company will use the new funds in the clinical development of its novel anticancer drug in lung and pancreatic cancer.
Inveready Seed Capital, Genoma España, shareholders, business angels and private investors participate in the funding.

AB-Therapeutics to participate at the annual meeting of Association of Cancer Research (EACR) in Barcelona, Catalonia, Spain

June 29, 2012

During the congress the company will present new data with the compound ABTL0812, on the mechanism of action and preclinical efficacy in experimental models of lung and pancreas, as well as data on toxicology and pharmacokinetics.
The work presented has been selected by the evaluation committee of the EACR.

AB-Therapeutics to Exhibit at the BIO 2012 International Convention in Boston, June 18-21, 2012 and to Present at Satellite Events.

June 15, 2012

AB-Therapeutics to participate at the annual meeting of the American Association of Cancer Research (AACR) in Chicago (USA)

March 12, 2012

During the congress the company will present the first data with the compound ABTL0812, on the mechanism of action and preclinical efficacy in experimental models of lung and pancreas.
The work presented has been selected by the evaluation committee of the AACR.

AB-Therapeutics to Present at the 5th Annual European Life Science CEO Forum for Partnering & Investing in Zurich (Switzerland), March 6-7, 2012.

March 1, 2012

AB-Therapeutics participates in the 10th Venture Capital Forum NEOTEC

AB-Therapeutics Announces the Launch of its New Web Site www.ab-therapeutics.com

June 15, 2011

AB-Therapeutics Announces Participation In Bio 2011 Annual International Convention in Washington, DC

June 14, 2011

AB-Therapeutics hold the First Meeting of its international Scientific Advisory Board

June 1, 2011

AB-Therapeutics Hires José Alfón as Director of Development

January 3, 2011

Alfón, previously at Palau Pharma, will head the Catalan company’s R&D

AB-Therapeutics new anticancer compounds reduce by 70% lung tumors growth

November 8, 2010

The Barcelona based biotech company is in a series-A fundraising round to conduct preclinical development and to file an IND in late 2011

LATEST NEWS

13.12.2017

News

AbilityPharma Announces FDA Approval of IND for Phase 2 Trial of ABTL0812 in Patients with Endometrial Cancer or Squamous Non-Small Cell Lung Cancer + info
05.10.2017

News

Ability Pharmaceuticals announces the approval from the French Medicines Agency ANSM to initiate a Phase 1/2a Clinical Trial with ABTL0812 to treat patients with endometrial cancer or squamous lung cancer as first-line therapy in France + info
18.09.2017

News

Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
07.03.2017

News

Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology + info
20.02.2017

News

Ability Pharmaceuticals launches a new updated website with a fresh design + info
15.12.2016

News

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
22.11.2016

News

Ability Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First Line Therapy in Patients with Endometrial or Squamous Lung Cancer Patients + info
11.05.2016

News

Ability Pharmaceuticals Enters into a Licensing Agreement with SciClone Pharmaceuticals for the Novel Anticancer Agent ABTL0812 for the China Market. + info
07.04.2015

News

Ability Pharmaceuticals Receives Positive Opinion from EMA for Orphan Drug Status of ABTL0812 in Pediatric Cancer Neuroblastoma. + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
Credits